"Click-able Development of Radiopharmaceuticals"
Date
Featured Speaker:
Joseph C. Walsh, PhD
Director of Radiochemistry
Siemens Molecular Imaging Biomarker Research (MIBR)
Culver City, California
Abstract: Personalized Medicine is an evolving medical paradigm relying on patient information to tailor therapy decisions. In order to truly personalize a therapeutic approach for a given patient, molecular information is required to precisely match the therapeutic approach with the causative biology. Positron emission tomography (PET) based imaging probes are uniquely suited to enable a Personalized Medicine approach. PET imaging provides both functional and physiological information as a 3D distribution map of all lesions in the patient simultaneously and non-invasively, which can be performed repeatedly during the course of treatment. Assessment of tumor pathology by PET imaging will be valuable to radiation oncologists, surgeons, biotechnology and pharmaceutical companies, who are engaged in developing target-based therapies or treatment strategies. Click Chemistry, a concept that employs only practical and reliable transformations for compound synthesis, has made a significant impact in several areas of chemistry, including the development of radiopharmaceuticals. The application of target-templated in situ click chemistry was used for PET probe lead generation. The reliable Cu(I)-catalyzed click reaction was employed for radiolabeling of glycopeptidic compounds without the need for protecting groups. Finally, the 1,2,3-triazole moiety was found to improve the pharmacokinetic properties of certain radiopharmaceuticals. In summary, the Click Chemistry approach for the discovery, optimization and labeling of new radiotracers, represents a very powerful tool for radiopharmaceutical development to support the evolving paradigm of Personalized Medicine.
Please note that Dr. Joseph C. Walsh is an applicant for the Biomarker Imaging faculty position.
Type
Time Duration
Featured Speaker:
Joseph C. Walsh, PhD
Director of Radiochemistry
Siemens Molecular Imaging Biomarker Research (MIBR)
Culver City, California
Abstract: Personalized Medicine is an evolving medical paradigm relying on patient information to tailor therapy decisions. In order to truly personalize a therapeutic approach for a given patient, molecular information is required to precisely match the therapeutic approach with the causative biology. Positron emission tomography (PET) based imaging probes are uniquely suited to enable a Personalized Medicine approach. PET imaging provides both functional and physiological information as a 3D distribution map of all lesions in the patient simultaneously and non-invasively, which can be performed repeatedly during the course of treatment. Assessment of tumor pathology by PET imaging will be valuable to radiation oncologists, surgeons, biotechnology and pharmaceutical companies, who are engaged in developing target-based therapies or treatment strategies. Click Chemistry, a concept that employs only practical and reliable transformations for compound synthesis, has made a significant impact in several areas of chemistry, including the development of radiopharmaceuticals. The application of target-templated in situ click chemistry was used for PET probe lead generation. The reliable Cu(I)-catalyzed click reaction was employed for radiolabeling of glycopeptidic compounds without the need for protecting groups. Finally, the 1,2,3-triazole moiety was found to improve the pharmacokinetic properties of certain radiopharmaceuticals. In summary, the Click Chemistry approach for the discovery, optimization and labeling of new radiotracers, represents a very powerful tool for radiopharmaceutical development to support the evolving paradigm of Personalized Medicine.
Please note that Dr. Joseph C. Walsh is an applicant for the Biomarker Imaging faculty position.